{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:33:04Z","timestamp":1789090384764,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572560"],"award-info":[{"award-number":["81572560"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Three-Year Action Plan of the Program of Shanghai Hospital Development Center for Promoting Clinical Skills and Innovative Ability of Municipal Hospitals","award":["16CR2012A"],"award-info":[{"award-number":["16CR2012A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We aimed to determine the prognosis value of circulating tumor cells (CTCs) undergoing epithelial\u2013mesenchymal transition in epithelial ovarian cancer (EOC) recurrence. We used CanPatrol CTC-enrichment technique to detect CTCs from blood samples and classify subpopulations into epithelial, mesenchymal, and hybrids. To construct nomogram, prognostic factors were selected by Cox regression analysis. Risk stratification was performed through Kaplan\u2013Meier analysis among the training group (n\u2009=\u2009114) and validation group (n\u2009=\u200938). By regression screening, both CTC counts (HR 1.187; 95% CI 1.098\u20131.752;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.012) and M-CTC (HR 1.098; 95% CI 1.047\u20131.320;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009) were demonstrated as independent factors for recurrence. Other variables including pathological grade, FIGO stage, lymph node metastasis, ascites, and CA-125 were also selected (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.005) to construct nomogram. The C-index of internal and external validation for nomogram was 0.913 and 0.874. We found significant predictive values for the nomogram with\/without CTCs (AUC 0.8705 and 0.8097). Taking CTC counts and M-CTC into separation, the values were 0.8075 and 0.8262. Finally, survival curves of risk stratification based on CTC counts (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0241), M-CTC (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0107), and the nomogram (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0021) were drawn with significant differences. In conclusion, CTCs could serve as a novel factor for EOC prognosis. Nomogram model constructed by CTCs and other clinical parameters could predict EOC recurrence and perform risk stratification for clinical decision-making.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Trial registration<\/jats:italic>\n                    Chinese Clinical Trial Registry, ChiCTR-DDD-16009601, October 25, 2016.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-86122-4","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T07:03:43Z","timestamp":1616396623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial\u2013mesenchymal transition"],"prefix":"10.1038","volume":"11","author":[{"given":"Jiani","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"86122_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330. https:\/\/doi.org\/10.3322\/caac.21590 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"86122_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"86122_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs, I. J. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945\u2013956. https:\/\/doi.org\/10.1016\/S0140-6736(15)01224-6 (2016).","journal-title":"Lancet"},{"key":"86122_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/bs.acc.2017.10.004","volume":"83","author":"LE Lowes","year":"2018","unstructured":"Lowes, L. E. & Allan, A. L. Circulating tumor cells and implications of the epithelial-to-mesenchymal transition. Adv. Clin. Chem. 83, 121\u2013181. https:\/\/doi.org\/10.1016\/bs.acc.2017.10.004 (2018).","journal-title":"Adv. Clin. Chem."},{"key":"86122_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","volume":"13","author":"S Riethdorf","year":"2007","unstructured":"Riethdorf, S. et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin. Cancer Res. 13, 920\u2013928. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1695 (2007).","journal-title":"Clin. Cancer Res."},{"key":"86122_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","volume":"10","author":"HI Scher","year":"2009","unstructured":"Scher, H. I. et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10, 233\u2013239. https:\/\/doi.org\/10.1016\/S1470-2045(08)70340-1 (2009).","journal-title":"Lancet Oncol."},{"key":"86122_CR7","doi-asserted-by":"publisher","first-page":"e0123976","DOI":"10.1371\/journal.pone.0123976","volume":"10","author":"S Wu","year":"2015","unstructured":"Wu, S. et al. Classification of circulating tumor cells by epithelial\u2013mesenchymal transition markers. PLoS ONE 10, e0123976. https:\/\/doi.org\/10.1371\/journal.pone.0123976 (2015).","journal-title":"PLoS ONE"},{"key":"86122_CR8","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-17-2459","volume":"78","author":"LN Qi","year":"2018","unstructured":"Qi, L. N. et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res. 78, 4731\u20134744. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2459 (2018).","journal-title":"Cancer Res."},{"key":"86122_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1021\/acscombsci.7b00146","volume":"20","author":"TA Burinaru","year":"2018","unstructured":"Burinaru, T. A. et al. Detection of circulating tumor cells using microfluidics. ACS Comb. Sci. 20, 107\u2013126. https:\/\/doi.org\/10.1021\/acscombsci.7b00146 (2018).","journal-title":"ACS Comb. Sci."},{"key":"86122_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","volume":"122","author":"A Poveda","year":"2011","unstructured":"Poveda, A. et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer. Gynecol. Oncol. 122, 567\u2013572. https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.028 (2011).","journal-title":"Gynecol. Oncol."},{"key":"86122_CR11","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","volume":"10","author":"WJ Allard","year":"2004","unstructured":"Allard, W. J. et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897\u20136904. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0378 (2004).","journal-title":"Clin. Cancer Res."},{"key":"86122_CR12","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1038\/s41598-019-43572-1","volume":"9","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Sci. Rep. 9, 7084. https:\/\/doi.org\/10.1038\/s41598-019-43572-1 (2019).","journal-title":"Sci. Rep."},{"key":"86122_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0346-4","volume":"39","author":"X Guan","year":"2019","unstructured":"Guan, X. et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial\u2013mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun. (Lond.) 39, 1. https:\/\/doi.org\/10.1186\/s40880-018-0346-4 (2019).","journal-title":"Cancer Commun. (Lond.)"},{"key":"86122_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4143\/crt.2018.508","volume":"51","author":"SI Kim","year":"2019","unstructured":"Kim, S. I. et al. Development of web-based nomograms to predict treatment response and prognosis of epithelial ovarian cancer. Cancer Res. Treat. 51, 1144\u20131155. https:\/\/doi.org\/10.4143\/crt.2018.508 (2019).","journal-title":"Cancer Res. Treat."},{"key":"86122_CR15","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran, V. P., Gonen, M., Smith, J. J. & DeMatteo, R. P. Nomograms in oncology: more than meets the eye. Lancet Oncol. 16, e173-180. https:\/\/doi.org\/10.1016\/S1470-2045(14)71116-7 (2015).","journal-title":"Lancet Oncol."},{"key":"86122_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1471-0528.2008.02033.x","volume":"116","author":"CG Gerestein","year":"2009","unstructured":"Gerestein, C. G. et al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 116, 372\u2013380. https:\/\/doi.org\/10.1111\/j.1471-0528.2008.02033.x (2009).","journal-title":"BJOG"},{"issue":"Suppl 24","key":"86122_CR17","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1002\/cncr.32474","volume":"125","author":"MA Bookman","year":"2019","unstructured":"Bookman, M. A. Can we predict who lives long with ovarian cancer?. Cancer 125(Suppl 24), 4578\u20134581. https:\/\/doi.org\/10.1002\/cncr.32474 (2019).","journal-title":"Cancer"},{"key":"86122_CR18","doi-asserted-by":"crossref","unstructured":"Harrell, Jr., F. E. rms: Regression Modeling Strategies. R package version 6.0-1. https:\/\/CRAN.R-project.org\/package=rms (2020)","DOI":"10.32614\/CRAN.package.rmsb"},{"key":"86122_CR19","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1158\/1078-0432.CCR-05-1769","volume":"12","author":"GT Budd","year":"2006","unstructured":"Budd, G. T. et al. Circulating tumor cells versus imaging\u2013predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12, 6403\u20136409. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1769 (2006).","journal-title":"Clin. Cancer Res."},{"key":"86122_CR20","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","volume":"12","author":"DF Hayes","year":"2006","unstructured":"Hayes, D. F. et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12, 4218\u20134224. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2821 (2006).","journal-title":"Clin. Cancer Res."},{"key":"86122_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ygyno.2003.08.004","volume":"91","author":"PL Judson","year":"2003","unstructured":"Judson, P. L. et al. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol. Oncol. 91, 389\u2013394. https:\/\/doi.org\/10.1016\/j.ygyno.2003.08.004 (2003).","journal-title":"Gynecol. Oncol."},{"key":"86122_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ygyno.2008.09.021","volume":"112","author":"T Fan","year":"2009","unstructured":"Fan, T., Zhao, Q., Chen, J. J., Chen, W. T. & Pearl, M. L. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol. Oncol. 112, 185\u2013191. https:\/\/doi.org\/10.1016\/j.ygyno.2008.09.021 (2009).","journal-title":"Gynecol. Oncol."},{"key":"86122_CR23","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1158\/1078-0432.CCR-14-0251","volume":"20","author":"W Guo","year":"2014","unstructured":"Guo, W. et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin. Cancer Res. 20, 4794\u20134805. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0251 (2014).","journal-title":"Clin. Cancer Res."},{"key":"86122_CR24","doi-asserted-by":"publisher","first-page":"571 e571","DOI":"10.1016\/j.ajog.2019.02.019","volume":"220","author":"S Cham","year":"2019","unstructured":"Cham, S. et al. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. Am. J. Obstet. Gynecol. 220, 571 e571-571 e578. https:\/\/doi.org\/10.1016\/j.ajog.2019.02.019 (2019).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"86122_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2015.08.011","volume":"139","author":"LR Duska","year":"2015","unstructured":"Duska, L. R., Java, J. J., Cohn, D. E. & Burger, R. A. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology\/gynecologic oncology group study (ADS-1236). Gynecol. Oncol. 139, 221\u2013227. https:\/\/doi.org\/10.1016\/j.ygyno.2015.08.011 (2015).","journal-title":"Gynecol. Oncol."},{"key":"86122_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2019.05.029","volume":"117","author":"CK Lee","year":"2019","unstructured":"Lee, C. K. et al. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. Eur. J. Cancer 117, 99\u2013106. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.029 (2019).","journal-title":"Eur. J. Cancer"},{"key":"86122_CR27","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.3802\/jgo.2018.29.e40","volume":"29","author":"G Bogani","year":"2018","unstructured":"Bogani, G. et al. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses. J. Gynecol. Oncol. 29, e40. https:\/\/doi.org\/10.3802\/jgo.2018.29.e40 (2018).","journal-title":"J. Gynecol. Oncol."},{"key":"86122_CR28","doi-asserted-by":"publisher","first-page":"33488","DOI":"10.1038\/srep33488","volume":"6","author":"DL Adams","year":"2016","unstructured":"Adams, D. L., Alpaugh, R. K., Tsai, S., Tang, C. M. & Stefansson, S. Multi-phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining. Sci. Rep. 6, 33488. https:\/\/doi.org\/10.1038\/srep33488 (2016).","journal-title":"Sci. Rep."},{"key":"86122_CR29","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.2147\/CMAR.S251271","volume":"12","author":"H Peng","year":"2020","unstructured":"Peng, H. et al. Clinical significance of red cell distribution width and circulating tumor cells with an epithelial\u2013mesenchymal transition phenotype in lung adenocarcinoma. Cancer Manag. Res. 12, 5105\u20135117. https:\/\/doi.org\/10.2147\/CMAR.S251271 (2020).","journal-title":"Cancer Manag. Res."},{"key":"86122_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/codi.14927","volume":"22","author":"J Hou","year":"2020","unstructured":"Hou, J., Guo, C. & Lyu, G. Clinical significance of epithelial\u2013mesenchymal transition typing of circulating tumour cells in colorectal cancer. Colorectal. Dis. 22, 581\u2013587. https:\/\/doi.org\/10.1111\/codi.14927 (2020).","journal-title":"Colorectal. Dis."},{"key":"86122_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3748\/wjg.v25.i1.138","volume":"25","author":"XH Zhao","year":"2019","unstructured":"Zhao, X. H. et al. Molecular detection of epithelial\u2013mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice. World J. Gastroenterol. 25, 138\u2013150. https:\/\/doi.org\/10.3748\/wjg.v25.i1.138 (2019).","journal-title":"World J. Gastroenterol."},{"key":"86122_CR32","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos, A., Schrag, D., Raj, G. V. & Panageas, K. S. How to build and interpret a nomogram for cancer prognosis. J. Clin. Oncol. 26, 1364\u20131370. https:\/\/doi.org\/10.1200\/JCO.2007.12.9791 (2008).","journal-title":"J. Clin. Oncol."},{"key":"86122_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell, F. E. Jr., Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361\u2013387. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19960229)15:4%3c361::AID-SIM168%3e3.0.CO;2-4 (1996).","journal-title":"Stat. Med."},{"key":"86122_CR34","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp, R. L., Dolled-Filhart, M. & Rimm, D. L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10, 7252\u20137259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713 (2004).","journal-title":"Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86122-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86122-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86122-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T10:40:47Z","timestamp":1724668847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86122-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86122"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86122-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-86051\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-86051\/v2","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6540"}}